Rodriguez-Pinto I, et al. - Authors evaluated the impact that triple therapy (anticoagulation plus CS plus plasma exchange and/or IVIGs) has on the mortality risk of patients with catastrophic anti-phospholipid syndrome (CAPS) included in the CAPS Registry. Findings suggested an independent association of the triple therapy with a higher survival rate among patients with CAPS when compared with non-treatment or treatment with other combinations of drugs included in the triple therapy. Patients who received triple therapy with plasma exchange or IVIGs, no statistical differences were noted between them.